CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
NCT03168256
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
528
Enrollment
INDUSTRY
Sponsor class
Conditions
Plaque Psoriasis
Interventions
DRUG:
CF101 2mg
DRUG:
CF101 3mg
DRUG:
Apremilast 30mg
DRUG:
Placebo Oral Tablet
Sponsor
Can-Fite BioPharma